Excimer lasers – Experience the material-friendly way of marking

Article

Experience the material-friendly way of marking.

Leading eye glass lens manufacturers continue moving their ophthalmic lens production to 193 nm excimer laser based marking and engraving for two reasons. First, UV laser pulses do not bear the risk of collateral damage around the mark thus creating higher yield and back-end savings. Second, excimer laser systems are well proven in the demanding refractive surgery market and have become affordable and turn-key.


Inscribing miniature brand logos and functional codes on hard and transparent ophthalmic lenses and blanks requires a material-friendly, high-resolution marking and engraving tool.

The deep-UV wavelength of excimer lasers eliminates the well known problems of cracking and melting which are due to thermal load effects of longer wavelength lasers. The good absorption i.e., the low optical penetration depth of the 193 nm wavelength in optically transparent glass and plastic substrates prevents bulk heating and delivers cold and precise marks and engravings on a micron scale.

Compact, high-repetition rate excimer lasers enable savings in cold marking and engraving of ophthalmic lenses due to their material-friendly 193 nm wavelength. The short UV pulses selectively remove transparent material such as polymers and glass without thermally induced stress. Excimer lasers deliver their cold pulses fast and precise with up to 500 Hz ensuring excellent process control.

www.coherent.com/excimer


PR Europe /MARCOM Excimer: petra.wallenta@coherent.com
Marketing Manager: Ralph.delmdahl@coherent.com

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.